-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Krystal Biotech, Raises Price Target to $386

Benzinga·08/04/2026 15:28:17
语音播报
Citigroup analyst Yigal Nochomovitz maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $378 to $386.